Using organoids to predict chemotherapy response in osteosarcoma
An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST
This study is trying to see how well different chemotherapy drugs work on osteosarcoma by testing them on tiny lab-grown versions of the tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06064682 on ClinicalTrials.gov |
What this trial studies
This study aims to determine the sensitivity of osteosarcoma to various chemotherapy agents by utilizing tissue cultures in the laboratory. Researchers will establish organoids from tumor samples obtained during routine biopsies or surgeries, allowing for the assessment of how these organoids respond to different treatments. The study will also incorporate genetic testing to enhance understanding of osteosarcoma and its treatment responses. The innovative miniaturized system developed allows for efficient testing of multiple drug combinations and treatment protocols on these organoids.
Who should consider this trial
Good fit: Ideal candidates include patients with imaging studies suggestive of osteosarcoma who are scheduled for a biopsy or surgery.
Not a fit: Patients who have already been diagnosed with osteosarcoma and are not undergoing biopsy or surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for patients with osteosarcoma.
How similar studies have performed: Other studies have shown promise in using organoid models for predicting treatment responses in various cancers, suggesting a potential for success in this novel approach for osteosarcoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion / exclusion criteria - Group1: \- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes Inclusion / exclusion criteria - Group 2: \- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Alice Soragni, PhD — University of California at Los Angeles
- Study coordinator: Summer Swearingen
- Email: SSwearingen@mednet.ucla.edu
- Phone: (424) 766-9349
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.